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A B S T R A C T
Parkinson’s disease (PD) is associated with degeneration of nigrostriatal neurons due to intracytoplasmic in-
clusions composed predominantly of a synaptic protein called α-synuclein. Accumulations of α-synuclein are
thought to ‘mask’ acetylation sites on histone proteins, inhibiting the action of histone acetyltransferase (HAT)
enzymes in their equilibrium with histone deacetylases (HDACs), thus deregulating the dynamic control of gene
transcription. It is therefore hypothesised that the misbalance in the actions of HATs/HDACs in neurodegen-
eration can be rectiﬁed with the use of HDAC inhibitors, limiting the deregulation of transcription and aiding
neuronal homeostasis and neuroprotection in disorders such as PD. Here we quantify histone acetylation in the
Substantia Nigra pars compacta (SNpc) in the brains of control, early and late stage PD cases to determine if
histone acetylation is a function of disease progression. PD development is associated with Braak-dependent
increases in histone acetylation. Concurrently, we show that as expected disease progression is associated with
reduced markers of dopaminergic neurons and increased markers of activated microglia. We go on to demon-
strate that in vitro, degenerating dopaminergic neurons exhibit histone hypoacetylation whereas activated mi-
croglia exhibit histone hyperacetylation. This suggests that the disease-dependent increase in histone acetylation
observed in human PD cases is likely a combination of the contributions of both degenerating dopaminergic
neurons and inﬁltrating activated microglia. The HDAC SIRT 2 has become increasingly implicated as a novel
target for mediation of neuroprotection in PD: the neuronal and microglial speciﬁc eﬀects of its inhibition
however remain unclear. We demonstrate that SIRT 2 expression in the SNpc of PD brains remains relatively
unchanged from controls and that SIRT 2 inhibition, via AGK2 treatment of neuronal and microglial cultures,
results in neuroprotection of dopaminergic neurons and reduced activation of microglial cells. Taken together,
here we demonstrate that histone acetylation is disease-dependently altered in PD, likely due the eﬀects of
dopaminergic neurodegeneration and microglial inﬁltration; yet SIRT 2 remains relatively unaltered with dis-
ease. Given the stable nature of SIRT 2 expression with disease and the eﬀects of SIRT 2 inhibitor treatment on
degenerating dopaminergic neurons and activated microglia detected in vitro, SIRT 2 inhibitors warrant further
investigation as potential therapeutics for the treatment of the PD.
1. Introduction
Parkinson’s disease (PD) is the second most common neurodegen-
erative disease, and the most prevalent movement disorder, presenting
clinically as cardinal symptoms of rigidity, tremor, and bradykinesia
[11,26]. These primary motor symptoms are the result of degeneration
of dopaminergic nigrostriatal pathways, thought to be due to
intracytoplasmic protein inclusions in dopaminergic neurons within the
Substantia Nigra pars compacta (SNpc), known as Lewy bodies and
Lewy neurites, composed predominantly of a synaptic protein called α-
synuclein (αSyn) [11,48]. Dopaminergic SNpc neurodegeneration in PD
is also associated with activation of the brain’s innate immune response,
with an activation of resident microglia in the brain [11,26]. Recruit-
ment of activated microglia to the SNpc in PD therefore leads to an
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upregulation and secretion of proinﬂammatory cytokines, such as Tu-
mour Necrosis Factor α (TNFα), Interleukin 6 (IL6) and Interleukin 1β
(IL1β), and activation of inducible Nitric Oxide Synthase (iNOS) re-
sulting in production of nitric oxide (NO) [23], which in turn are
thought to exacerbate degeneration of dopaminergic SNpc neurons
[11]. In recent years epigenetic mechanisms such as DNA methylation
and histone remodelling through acetylation have also become im-
plicated in PD pathogenesis [2], and as such have become increasingly
studied in PD pathogenesis.
In healthy cells there is a tightly controlled equilibrium between the
eﬀects of histone acetyltransferases (HATs) and histone deacetylases
(HDACs) enabling histone (de)acetylation and the dynamic control of
gene transcription [13,45]. In healthy neurons this results in appro-
priate regulation of gene expression and subsequently facilitates ap-
propriate neuronal homeostasis [45]. In neurodegenerative disease
however, there is known to be an imbalance between the activities of
HATs and HDACs in favour of histone deacetylation, thought to be
pathogenic in disease progression [13,43,45]. This misbalance in neu-
rodegeneration was ﬁrst noted in both an in vitro model of cortical
neuronal cell death induced by activation of amyloid precursor protein
signalling, a hallmark of Alzheimer’s disease, and in an in vivo model of
amyotrophic lateral sclerosis: the G86R mutant SOD-1 mice displaying
motor neuron degeneration [43]. More speciﬁc to PD, we demonstrated
recently that intracellular protein accumulation in a ubiquitin protea-
some inhibitor rat model of PD results in histone hypoacetylation [21].
Likewise αSyn accumulation itself has been shown to promote histone
H3 hypoacetylation as ascertained from overexpression studies in SH-
SY5Y cells as well as in an in vivo αSyn transgenic drosophila model,
thought to be achieved through αSyn ‘masking’ acetylation sites on
histone proteins [31]. From these ﬁndings then it is hypothesised that
the misbalance in the activities of HATs/HDACs could be rectiﬁed with
the use of HDAC inhibitors (HDACIs) to reduce the extent of cell death
in the nigrostriatal pathways in PD [10,13,19,22,29]. For example,
inhibitions of HDACs 1 and 2 [9], and 6 [27,38], as well as broader
inhibitors of entire HDAC classes such as I and IIa [20,21,36], and IIb
[50], have all been demonstrated recently to be neuroprotective in
models of PD. Notably, inhibition of the class III HDAC, Silent In-
formation Regulator 2 (SIRT 2), has become increasingly implicated as
a novel target for mediation of neuroprotection in PD
[8,12,14,16,17,32,34,52]. For example, Outeiro et al. [34] have pre-
viously demonstrated that AGK2, a potent inhibitor of SIRT 2 dose
dependently protects dopaminergic neurons from death in a transgenic
αSyn overexpressing drosophila models of PD.
Although the neuroprotective phenotype of HDAC selective, such as
SIRT 2, inhibitors have been demonstrated in vivo in animal models of
PD, thus far pathogenic histone hypoacetylation and transcriptional
dysfunction in the nigrostriatal of PD is yet to be conﬁrmed. The
acetylation level of histones within degenerating regions of the
Parkinsonian brain must therefore be quantiﬁed and compared with age
matched control subjects to conﬁrm this hypothesis in the human dis-
ease and rationalise the use of HDACIs for the treatment of PD.
Additionally, although it is thought that pathogenic histone hypoace-
tylation is in part due to the ‘masking’ eﬀects of αSyn aggregates toward
histone proteins, it remains unanswered whether the expression levels
of HDACs in the brain are aﬀected in PD. This is crucial as without
conﬁrming the maintenance of HDAC expression levels in the
Parkinsonian brain, the use of HDACIs for therapeutic use in PD cannot
be rationalised. Therefore here, for the ﬁrst time, we quantify histone
acetylation levels in the SNpc, the area known to predominantly de-
generate with PD development, in brain tissue from both early (Braak
stage 3/4 [3]) and late (Braak stage 6 [3]) stage PD cases, as well as age
matched controls, to determine if histone acetylation is indeed a func-
tion of PD development. Additionally, given the implication of the use
of HDAC (such as SIRT 2) inhibitors for neuroprotection in PD, we
quantify HDAC expression in the SNpc of these same cases, to de-
termine if the expression level of these enzymes changes with PD
development. Furthermore, we seek to validate the neuroprotective and
anti-inﬂammatory potential of SIRT 2 inhibition with the use of cell
culture models of dopaminergic neurodegeneration and microglial ac-
tivation, respectively, highlighting this HDAC as a potential therapeutic
target for the treatment of PD.
2. Materials and methods
2.1. Human brain tissue
Human brain tissue samples (PD and aged-matched controls) were
obtained from the Parkinson’s UK Tissue Bank at Imperial College
London, and all experiments using the tissue samples were previously
approved by the PUKTB’s Ethical Review Panel. Tissue from 10 control
cases (4♂: 6♀, 82.1 ± 1.9 years), 8 early PD cases (Braak stage
3.5 ± 0.2, 4♂: 4♀, 79.3 ± 1.8 years), and 12 late PD cases (Braak
stage 6 ± 0, 4♂: 4♀, 79.3 ± 1.8 years) were included for study, and
data presented represents all cases studied. Cases were selected based
upon the Tissue Bank’s availability of snap frozen tissue from the cen-
tral region of the SNpc, in Braak stage 3-4, and Braak stage 6 PD cases,
and healthy age matched controls. The suitability of tissue and sam-
pling of the central SNpc was determined and performed by an ex-
perienced Tissue Bank technician at time of sample retrieval.
Supplementary Table 1 summarises the cases used, including case by
case age at death, cause of death, post-mortem delay, and for PD cases,
age at disease onset, disease duration, Braak stage, and any PD medi-
cation taken in life.
2.2. Cell cultures
The rat mesencephalic dopaminergic 1RB3AN27 (N27) cell line
possesses both biochemical and physiological properties of dopami-
nergic neurons [1], making it an ideal candidate cell line for the
modelling of the Parkinsonian dopaminergic neuronal cell death in
vitro. Prior to experimentation, N27 expression of NeuN and TH were
conﬁrmed by western blot analysis (see below for methods), conﬁrming
the dopaminergic neuronal phenotype of this cell line (supplementary
Fig. 1). N27 cells (Millipore, UK) (up to passage number 45) were
maintained in RPMI 1640 medium (Sigma, UK) supplemented with
10% foetal calf serum, 2mM L-glutamine, 50U/ml Penicillin and 50 μg/
ml Streptomycin (all Gibco, UK) (complete N27 medium), in a humi-
diﬁed incubator temperature controlled at 37 °C and with 5% CO2
ventilation. For experimentation, neurons were seeded into 96 well
plates (Corning, UK) at a density of 10×10^3 cells/well, and left for
24 h to allow neurons to readopt their natural morphology. On the day
of experiments cell medium was removed and replaced with fresh
complete N27 medium. For induction of neurodegeneration, N27 cells
were treated with lactacystin (Enzo Life Sciences, UK) (0.75 μM in
distilled phosphate buﬀered saline (DPBS) (Sigma, UK)) for 24 h as this
was shown to produce suitable robust sub-maximal levels of cytotoxi-
city (data not shown). For SIRT 2 inhibitor treatment, N27 cells were
pre-treated with AGK2 (Tocris, UK) (in DPBS) for 24 h as this timepoint
was shown produce signiﬁcant hyperacetylation (supplementary
Fig. 2).
The mouse microglial (N9) cell line stably retains microglial phe-
notypic cell surface markers, and most importantly are stringently ac-
tivated upon treatment with LPS [41] making them an ideal cell line for
the study of microglial activation in vitro. Prior to experimentation, N9
expression of Iba-1 was conﬁrmed by western blot analysis (see below
for methods), conﬁrming the microglial phenotype of this cell line
(supplementary Fig. 1). N9 cells (a kind gift from Dr Deanne Taylor) (up
to passage number 45) were maintained in Dulbecco's Modiﬁed Eagle's
Medium (Sigma, UK) supplemented with 5% foetal calf serum, 4mM L-
glutamine, 50U/ml Penicillin and 50 μg/ml Streptomycin (complete N9
medium), in a humidiﬁed incubator temperature controlled at 37 °C
and with 5% CO2 ventilation. For experimentation, microglia were
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seeded into 6 well plates (Corning, UK) at a density of 500×10^3 cells/
well, and left for 24 h to allow microglia to readopt their natural
morphology. On the day of experiments cell medium was removed and
replaced with fresh complete N9 medium (2ml per well). For induction
of microglial activation, N9 cells were treated with LPS (from Escher-
ichia coli O111:B4, Sigma, UK) (125 ng/ml in DPBS) for 24 h as this was
shown to produce signiﬁcant yet sub-maximal production of both NO
and TNFα (data not shown). For SIRT 2 inhibitor treatment, N9 cells
were pre-treated with AGK2 (in DPBS) for 48 h as this timepoint was
shown produce signiﬁcant hyperacetylation (supplementary Fig. 2).
2.3. Protein and mRNA extraction
For extraction of protein and mRNA from human brain tissue
samples, 30mg of tissue from the brain block containing the SNpc for
each case was collected into ribonuclease (RNase)-free microcentrifuge
tubes (Ambion, UK). Brain tissue was homogenised in QIAzol® Lysis
Reagent (Qiagen, UK) using a tissue homogeniser (Ultra-Turrax T18,
IKA, Germany). mRNA and protein was extracted from homogenised
brain tissue using the RNeasy® Plus Universal Mini Kit (Qiagen, UK) as
per the manufacturer’s instructions. Isolated RNA was quantiﬁed
spectrophotometrically using a NanoDrop ND-1000 spectrophotometer
(Thermo Fischer Scientiﬁc, USA) and RNA purity veriﬁed by an average
A260/280 ratio of 1.99 (range 1.97-2.01). The quantity of isolated protein
was determined using the 96-well variant of the Bradford Assay (Sigma,
UK): colour change determined using a 96-well plate reader (VersaMax
Microplate Reader, Molecular Devices, UK) at 595 nm (A595). mRNA
and protein were stored at −80 °C and −20 °C respectively until fur-
ther analysis.
For extraction of protein from cell cultures, Radio-
Immunoprecipitation Assay (RIPA) buﬀer (Sigma, UK) was used as per
the manufacturer’s instructions. Brieﬂy, after incubation of cells with
the test compound(s) for the appropriate time period in a 6 well plate,
the growth medium was removed and cells were washed twice with ice
cold DPBS to remove any residual medium. After this cells were in-
cubated with RIPA buﬀer with 1% protease inhibitor cocktail (Sigma,
UK) (200 μl/well) on ice for 5mins. Cells were then scraped manually
from the surface using a sterile scraper (VWR, UK) to removed and lyse
residual cells. Cell lysate was collected and clariﬁed to remove dena-
tured nucleic acid by centrifugation and 8000 g for 10mins at 4 °C. The
protein containing supernatant was then transferred to new tubes and
quantiﬁed using the Bradford assay (Bradford Reagent, Sigma, UK).
Proteins were stored at −20 °C until further Western blot analysis.
2.4. Western blot analyses
Laemmli sample buﬀer (Sigma, UK) was added to 10 μg extracted
protein sample from either human tissue or cell cultures, and denatured
by incubating at 95 °C for 15mins. Samples were loaded onto a 1mm
thick hand-cast 15% Tris-Glycine gel and proteins were separated by
electrophoresis (65mA for 40mins). Proteins were transferred onto
methanol soaked PVDF membrane (Millipore, UK) with a pore size of
0.45 μm using semi-dry transfer (20 V for 45mins). Membranes were
then equilibrated in TBS containing 0.2% Tween-20 (TBS-T) (Sigma,
UK), before being blocked in 5% non-fat milk (Sigma, UK) in TBS-T for
1hr at room temperature. Membrane was washed in TBS-T again before
being incubated in primary antibodies against either histone protein H3
acetylated on lysine 9 (rabbit anti-AcH3-Lys9, Sigma, UK, 1:10,000)
and mouse anti-β-actin antibody (1:20,000, Abcam, UK) for 1hr at RT,
or tyrosine hydroxylase (rabbit anti-TH, Millipore, UK, 1:1000) and
NeuN (mouse anti-NeuN, Millipore, UK, 1:1000) for 20 h at RT, or Iba-1
(rabbit anti-Iba-1, Wako, Japan, 1.67 μg/ml) for 20hr at 4 °C.
Membranes were then washed again and incubated in horseradish
peroxidase (HRP)-conjugated secondary antibodies (either Goat anti-
Rabbit [1:10,000] (for detection of rabbit anti- AcH3-Lys9, TH, and Iba-
1) and Horse anti-Mouse [1:10,000] (for detection of mouse anti-β-
actin, and NeuN), both Vector Laboratories, UK) for 1hr at RT.
Membranes were washed again in TBS-T and developed using chemi-
luminescence (Clarity Western ECL Substrate, Bio-Rad, UK). Bands
were quantiﬁed using densitometry analysis software (ImageJ, v1.4).
For Western blot analysis of human brain derived proteins, the 30
samples were run on 3 separate gels, each gel containing samples from
all three disease groups. Additionally, β-actin was used as a loading
control for all samples, and AcH3-Lys9 expression shown relative to β-
actin content, and as a percentage of the control subject group.
2.5. Quantitative real time polymerase chain reactions
For cDNA synthesis, 500 ng of total RNA from each sample was
reverse transcribed according to the manufacturer's instructions using
the QuantiTect® reverse transcription kit (Qiagen, UK) with integrated
removal of genomic DNA contamination. The reactions were stored at
−20 °C until further use. Real-time reverse transcriptase quantitative
polymerase chain reaction (RT-qPCR) experiments were performed
using a Mx3000P™ real-time PCR system with MxPro software (v4.10,
Stratagene, USA) and the Brilliant® II QPCR master mix with low ROX
(Agilent technologies UK Ltd, UK). For each gene of interest in each
sample, 20 μl reactions were set up in triplicate, and run in duplex with
a novel reference gene (XPNPEP1 [X-prolyl aminopeptidase (amino-
peptidase P) 1] [15]), with each reaction containing 10 μl 2×Brilliant®
II QPCR master mix, 7 μl RNase-free water, 1 μl template cDNA, 2 μl
(1 μl gene of interest+ 1 μl reference gene) 10×PrimeTime™ qPCR
assays (Integrated DNA technology, USA). See supplementary Table 2
for probe and primer sequences. Reactions were carried out with the
following cycling protocol: 95 °C for 10min, then 60 cycles with a 3-
step program (95 °C for 30s, 55 °C for 30 s and 72 °C for 30s). Fluores-
cence data collection was performed during the annealing step. A ne-
gative control containing no cDNA template was also run in each plate.
Similarly, an inter-plate calibrator, created by pooling control cDNA
samples, was also run in each plate. Relative gene expression was de-
termined using the 2−DΔCT method normalising to the expression of the
novel reference gene [15] and the appropriate control group.
2.6. Cell viability assays
2.6.1. MTS assay
For performing the MTS assay the CellTiter 96® AQueous One
Solution Cell Proliferation Assay Kit (Promega, USA) was used as per
the manufacturer’s instructions. Brieﬂy, after incubation of cells with
the test compound(s) for the appropriate time period in a 96 well plate
in triplicate, 20 μl CellTiter 96® AQueous One Solution reagent was
added directly to each well containing 100 μl cell culture medium.
Plates were then incubated at 37 °C in a humidiﬁed incubator tem-
perature with 5% CO2 ventilation for 3 h. Absorbance was read using a
96-well plate reader at 490 nm (A490). The absorbance at 490 nm
(A490) was then converted to% of control group and data expressed as
mean ± standard error or mean (SEM).
2.6.2. Neutral red assay
For performing the NR assay a previously published protocol was
followed [40]. Brieﬂy, NR stock solution (4mg/ml NR dye (Sigma, UK)
in DPBS) was dissolved into complete cell culture medium (either N9 or
N27 depending on the cell line tested) to give a ﬁnal concentration of
40 μg/ml NR (henceforth referred to as NR medium) and incubated at
37 °C for 24 h. To perform the assay, after incubation of cells with the
test compound(s) for the appropriate time period in a 96 well plate in
triplicate, the test medium was removed by aspiration and replaced
with 100 μl neutral red medium. Plates were incubated at 37 °C in a
humidiﬁed incubator temperature controlled at 37 °C and with 5% CO2
ventilation for 3 h. After this time cells were inspected using an inverted
microscope to conﬁrm intracellular precipitation of NR. The NR
medium was removed by aspiration from wells and cells washed by
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adding 150 μl DPBS and removing by aspiration. 150 μl NR destain
solution (50% ethanol, 49% water, 1% glacial acetic acid (all Sigma,
UK)) was added to wells before plates were shaken rapidly on a mi-
crotitre plate shaker for 10mins to solubilise the dye. Absorbance was
read using a 96-well plate reader at 540 nm (A540). The absorbance at
540 nm (A540) was converted to% of control group and data expressed
as mean ± SEM.
2.6.3. Bradford assay
Brieﬂy, after spectrophotometric reading of the wells for the NR
assay, the neutral red destain solution was removed from wells by as-
piration before cells were washed three times with 150 μl DPBS. Cells
were then lysed and proteins solubilised by addition of 50 μl sodium
hydroxide (0.1M) (Sigma, UK) solution. Protein standards were run in
parallel with each plate by addition of 50 μl sodium hydroxide (0.1 M)
solution to 5 μl of a known concentration of protein (0 − 1.4mg/ml
BSA (Sigma, UK) in dH20) run in triplicate. 200 μl Bradford Reagent
was added to each well and plates were shaken rapidly on a microtitre
plate shaker for 20mins. Absorbance was read using a 96-well plate
reader at 595 nm (A595). A standard curve of the spectrophotometric
reading at A595 for each standard, minus the reading for the standard
void of protein was plotted against its protein concentration. The slope
of the line of best ﬁt of this data set was used for calculation of the
protein concentration for cell lysates. Data was converted to% of con-
trol group and data expressed as mean ± SEM.
2.6.4. Microglial activation assays
2.6.4.1. Griess assay. In biological systems, NO is auto-oxidised into
two stable metabolites: nitrite (NO2−) and nitrate (NO3−). The Griess
Assay was therefore used for determination of one of these metabolites,
nitrite, as an indicator of NO production. For performing the Griess
assay, after incubation of microglial cells with the test compound(s) for
the appropriate time period in a 6 well plate, the medium was removed
and centrifuged at 1200g for 5mins to removed cell debris. 100 μl of
medium samples were pipetted into a 96 well plate in triplicate. In
parallel, standards of known nitrite concentration (0 − 50 μM sodium
nitrite (Sigma, UK) in complete N9 medium) were run in triplicate in
order to translate the spectrophotometric reading to nitrite
concentration. 100 μl Griess Reagent (Sigma, UK) was added directly
to each well and plates were shaken rapidly on a microtitre plate shaker
for 10mins. Absorbance was read using a 96-well plate reader at
540 nm (A540). A standard curve of the spectrophotometric reading
at A540 for each standard, minus the reading for the standard void of
nitrite was plotted against its nitrite concentration. The slope of the line
of best ﬁt of this data set was used for calculation of the nitrite
concentration for medium samples. Data was converted to% of control
group and data expressed as mean ± SEM.
2.6.4.2. TNFα enzyme-linked immunosorbant assays. For performing
TNFα ELISAs, murine TNFα ELISA development kits (Peprotech Ltd.,
UK) were used as per the manufacturer’s instructions. Brieﬂy, the
surface of a high binding EIR/RIA 96 well plate (Corning, UK) was
coated with the anti-TNFα capture antibody (1 μg/ml in PBS) overnight
at RT. After this time, wells were washed four times in PBST (PBS with
0.05% Tween-20). Non-speciﬁc binding was then blocked by incubating
wells with PBS with 1% BSA for 1hr at RT. Wells were then washed
again four times with PBST and incubated with either sample or
standard (0–2 ng/ml TNFα in PBS with 0.05% Tween-20 and 0.1%
BSA) run in triplicate and incubated for 2 h at RT. Wells were then
washed again four times in PBST and incubated with anti-TNFα
detection antibody (0.25 μg/ml) for 2 h at RT. Wells were washed
again four times in PBST and incubated in avidin complex (1:2000
TNFα in PBS with 0.05% Tween-20 and 0.1% BSA) for 30mins at RT.
Wells were washed a ﬁnal four times in PBST and 100 μl of ABTS added
to each well. Absorbance was read using a 96-well plate reader at
405 nm and 650 nm (A405 and A650, respectively). Colour
development was monitored for ∼45mins and the reading in which
the A405nm was ≤0.2 for the 0 ng/ml TNFα standard and ≤1.4 for the
2 ng/ml TNFα as per the manufacturer’s instruction. A standard curve
of the spectrophotometric reading at A405 minus the reading at A650
was plotted against TNFα. The equation of this line of best ﬁt was then
used for calculation of the TNFα concentration for medium samples.
Data was then converted to% of control group and data expressed as
mean ± SEM.
2.7. Statistics
A one way ANOVA with Bonferroni post-test was used to compare
AcH3-Lys9 expression between human control and PD cases. Linear
regression analyses were used to test correlations between data. A two-
way ANOVA with Bonferroni post-test was used to compare TH and
HLA-DPα1 expression, and HDAC expressions between human control
and PD cases. Unpaired t-tests were used for comparison of treated cell
lines to vehicle treated lines. Lastly, a one-way ANOVA with Dunnett
post-test was used to compare AGK2-treated cell lines to vehicle treated
lines. All data, unless otherwise stated, is presented as mean ±
standard error of mean, from all human cases described (supplemen-
tary Table 1) or n=3 independent repeats for cell culture experiments.
All statistical tests were performed using GraphPad Prism (v5.0 for
Windows, GraphPad Software, San Diego, CA, USA).
3. Results
3.1. Histone acetylation in the SNpc of the human brain during PD
development
Quantiﬁcation of the commonly acetylated histone residue, AcH3-
Lys9, in protein extracts from the SNpc of control, early, and late PD
cases (see supplementary Table 1) revealed a disease-dependent in-
crease in acetylation of this residue on histone 3 in this brain region.
There was a subtle increase in AcH3-Lys9 observed from control in
early PD cases and signiﬁcantly more AcH3-Lys9 from control in late
Fig. 1. Histone Acetylation and Parkinson’s Disease
Progression.
Histone acetylation (AcH3-Lys9) was quantiﬁed in
the Substantia Nigra pars compacta (SNpc) of each
control, each early, and each late PD case relative to
β-Actin using Western blot analysis. (A) Bar graph
illustrating level of AcH3-Lys9 observed in each
group of cases. (B) Representative blot of data pre-
sented in (A). (C) Graphical representation of corre-
lation between Braak Stage of human cases and
AcH3-Lys9 observed in the SNpc of that case. N= 8-
12 per group (see supplementary Table 1). Statistical
signiﬁcance indicated with asterisks: *p < .05.
Abbreviations: ePD, early Parkinson’s disease; lPD,
late Parkinson’s disease.
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stage PD cases (Fig. 1A and B, early and late PD cases,
132.70 ± 34.16% and 185.11 ± 17.61% of control respectively,
p > .05 and p < .05). Correlation analysis between the level of his-
tone acetylation and the Braak stage of each case revealed a signiﬁcant
correlation between these two measures, indicative of histone acetyla-
tion in the SNpc with PD development (Fig. 1C, R2= 0.1937, p < .05).
3.2. Changes in expression of TH, HLA-DPα1 and SIRT 2 in the SNpc with
PD development
As would be expected, the mRNA expression level of tyrosine hy-
droxylase (TH), the rate limiting enzyme in monoamine synthesis, was
disease-dependently reduced, in line with degeneration of dopami-
nergic neurons in the SNpc in PD (Fig. 2, early and late PD cases,
0.55 ± 0.25 and 0.22 ± 0.09 fold change from control respectively,
p > .05 and p < .05). Correlation analysis between the level of SNpc
mRNA TH expression and the Braak stage of each case revealed a sig-
niﬁcant negative correlation between these two measures (Table 1,
R2= 0.2216, p < .01). The opposite was true for expression of Human
Leukocyte Antigen DPα1 (HLA-DPα1), a MHC protein known to be
present on activated inﬁltrating microglia: a disease-dependent increase
in HLA-DPα1 mRNA expression being observed with PD development
(Fig. 2, early and late PD cases, 1.73 ± 0.23 and 1.80 ± 0.20 fold
change from control respectively, p > .05 and p < .05). Correlation
analysis between the level of SNpc HLA-DPα1 mRNA expression and
the Braak stage of each case revealed a signiﬁcant positive correlation
between these two measures (Table 1, R2= 0.1585, p < .05). Inter-
estingly however, probably due to the large amount of TH positive cell
death with disease development, histone acetylation (AcH3-Lys9) cor-
related only with HLA-DPα1 mRNA expression in the SNpc of diseased
brain tissue (Table 1, R2= 0.2951, p < .01), not TH mRNA expression.
The expression levels of HDACs 1-10, and SIRTs 1 and 2, did not
follow such a disease-dependent pattern: revealing no statistically sig-
niﬁcant changes in expression between either early or late PD cases
compared from controls (Table 2). Of note, SIRT 2 expression in the
early PD cases was 41.80 ± 10.67% reduced compared to control
cases, however in late stage PD cases SIRT 2 expression was reduced by
only 12.53% ± 14.74% (Fig. 2B). Correspondingly, SIRT 2 expression
did not correlate with either Braak staging of cases or the level of his-
tone acetylation, indicative of a more complex mechanism of disease-
dependent change (Table 1). Comparable levels of inﬁltrating microglia
(HLA-DPα1 expression) between early and late stage cases, combined
with exacerbated levels of dopaminergic neurodegeneration (TH ex-
pression) in late stage cases compared to early however could explain
this pattern of change.
Fig. 2. Relative mRNA Expression of TH, HLA-DPα1
and SIRT 2 in Control and PD SNpc Tissue Samples.
(A) mRNA expression levels of cellular markers TH
and HLA-DPα1 in the SNpc of control and PD cases,
relative to a housekeeping gene expression, quanti-
ﬁed using qRT-PCR. (B) mRNA expression levels of
the HDAC SIRT 2 in the same cases. N= 8-12 per
group (see supplementary Table 1). Statistical sig-
niﬁcance indicated with asterisks: *p < .05.
Abbreviations: TH, tyrosine hydroxylase; HLA-PDα,
Human Leukocyte Antigen DPα1, SIRT 2, Silent
Information Regulator 2; ePD, early Parkinson’s dis-
ease; lPD, late Parkinson’s disease.
Table 1
Results of Regression Analyses Performed Between TH, HLA-DPα, SIRT2 Expression and Braak Stage and AcH3-Lys9 Expression.
Correlation Slope R2 P Value
Braak Stage vs. TH −0.1311 ± 0.04641 0.2216 0.0086 **
HLA-DPα 0.1384 ± 0.06649 0.1585 0.0487 *
SIRT 2 −0.02307 ± 0.03272 0.01744 0.4866
AcH3-Lys9 vs. TH −0.001152 ± 0.001835 0.01438 0.5355
HLA-DPα 0.006618 ± 0.002181 0.2951 0.0061 **
SIRT 2 2.038e-005 ± 0.001156 0.00001151 0.9861
Abbreviations: TH, tyrosine hydroxylase; HLA-PDα, Human Leukocyte Antigen DPα1, SIRT 2, Silent Information Regulator 2. N=8-12 per group (see supplementary Table 1).
Table 2
Results of Changes in Expression of HDACs in the SNpc of Control and PD cases.
Class Isoform Relative Expression (Fold Change From Control)
Early PD Late PD
Mean ± SEM P Value Mean ± SEM P Value
I HDAC1 1.2357 ± 0.1152 >0.05 1.0550 ± 0.1852 >0.05
HDAC2 1.2852 ± 0.2858 >0.05 1.1276 ± 0.1603 >0.05
HDAC3 0.4194 ± 0.0387 >0.05 0.5014 ± 0.0673 >0.05
HDAC8 0.6861 ± 0.1515 >0.05 1.2577 ± 0.2154 >0.05
IIa HDAC4 1.0481 ± 0.2123 >0.05 0.8516 ± 0.2084 >0.05
HDAC5 0.3724 ± 0.2360 >0.05 0.7682 ± 0.1731 >0.05
HDAC7 0.7703 ± 0.1198 >0.05 0.4296 ± 0.0700 >0.05
HDAC9 1.0882 ± 0.1929 >0.05 0.8917 ± 0.1041 >0.05
IIb HDAC6 1.3227 ± 0.2378 >0.05 0.7030 ± 0.1087 >0.05
HDAC10 1.0997 ± 0.2442 >0.05 0.7087 ± 0.1079 >0.05
III SIRT1 1.0097 ± 0.1486 >0.05 0.8456 ± 0.0556 >0.05
SIRT2 0.5819 ± 0.1067 >0.05 0.8747 ± 0.1473 >0.05
Abbreviations: HDAChistone deacetylase; PDParkinson’s disease; SEMstandard error of
mean. N=8–12 per group (see supplementary Table 1).
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3.3. Histone acetylation levels in degenerating dopaminergic neurons and
activated microglia in culture reveal opposing eﬀects of pathology
To isolate the eﬀects of neurodegeneration through altered protein
accumulation on histone acetylation in dopaminergic neurons, and the
eﬀects of microglial activation on histone acetylation, cell culture sys-
tems were utilised. Incubation of N27 mesencephalic dopaminergic
neurons with the irreversible ubiquitin proteasome inhibitor, lacta-
cystin, for 24 h induced a signiﬁcant degree of neurodegeneration, cell
viability quantiﬁed through the MTS, neutral red, and Bradford assays
(Fig. 3A, lactacystin vs. vehicle treated neurons, p < .001 in all three
assays). Accompanying this, degenerating dopaminergic N27 neurons
were observed to have a signiﬁcantly decreased level of histone acet-
ylation compared to vehicle treated neurons (Fig. 3C and D, AcH3-Lys9
relative to β-Actin, 0.31 ± 0.05 in vehicle treated vs. 0.19 ± 0.04 in
lactacystin treated neurons, p < .05). Incubation of N9 microglial cells
with lipopolysaccharide (LPS) for 24 h induced a signiﬁcant degree of
microglial activation, indirectly measured through quantiﬁcation of NO
and TNFα secreted into the cell culture medium (Fig. 3B, LPS vs. vehicle
treated microglia, p < .001 in both assays). Accompanying this, acti-
vated N9 microglia were observed to have a signiﬁcant increase in
histone acetylation compared to vehicle treated microglia (Fig. 3,
AcH3-Lys9 relative to β-Actin, 0.38 ± 0.07 in vehicle treated vs.
0.64 ± 0.06 in lactacystin treated neurons, p < .05). These ﬁndings
are therefore in agreement with those above, in which a strong corre-
lation between histone acetylation and PD development was observed,
in line with both a disease-dependent reduction in dopaminergic
neuron marker and increase in activated microglial marker.
3.4. SIRT 2 inhibition translates to neuroprotection in neuronal cell cultures
Neurodegeneration of dopaminergic N27 neurons exerted by lac-
tacystin (0.75 μM), has been shown above to produce signiﬁcant his-
tone hypoacetylation. Therefore to determine whether or not histone
acetylation through SIRT 2 inhibition would translate to neuroprotec-
tion in vitro, dopaminergic N27 cells were treated with a range of
concentrations (1pM to 100 μM) of AGK2, a potent SIRT 2 inhibitor,
prior to treatment with lactacystin (0.75 μM) to cause degeneration.
Cell viability was then quantiﬁed using MTS, Neutral Red, and Bradford
assays. In all three viability assays neurotoxicity was observed at AGK2
concentrations ≥10 μM (Fig. 4A, B and C). However, treatment of N27
neurons with 1 μM AGK2 prior to treatment with lactacystin resulted in
a signiﬁcant increase in cell viability compared with vehicle treated
cells, in all three assays (Fig. 4A, B and C, 1 μM AGK2, p < .05 for each
assay).
3.5. SIRT 2 inhibition translates to anti-inﬂammation in microglial cell
cultures
Activation of N9 microglial cells through treatment with LPS
(125 ng/ml), has been shown above to produce signiﬁcant histone hy-
peracetylation. To determine the eﬀects of SIRT 2 inhibition on mi-
croglial activation, N9 microglia were treated with a range of con-
centrations (10 nM to 10 μM) of AGK2, prior to treatment with LPS
(125 ng/ml) to trigger activation. Quantiﬁcation of secreted NO and
TNFα from N9 microglia were used as surrogate markers of activation
as a result of LPS treatment. Cell culture medium concentrations of both
NO and TNFα were observed to be signiﬁcantly reduced in N9 micro-
glia treated with 10 μM AGK2 compared with vehicle treatment (Fig. 5A
and B, p < .05 in both assays), indicative of reduced microglial acti-
vation at this concentration. To conﬁrm that the observed reductions in
NO and TNFα were indeed a result of reduced microglial activation and
not cytotoxicity, cell viability after AGK2 and LPS treatment was
quantiﬁed using MTS, Neutral Red, and Bradford assays. No cytotoxi-
city was observed at any concentration of AGK2 tested (Fig. 4C).
4. Discussion
Here we have demonstrated for the ﬁrst time that histone acetyla-
tion within the SNpc positively correlates with PD pathological devel-
opment in the human brain, which is associated with neurodegenera-
tion of dopaminergic neurons. This is in contrast to our in vitro ﬁndings,
in which histone hypoacetylation was observed in degenerating dopa-
minergic neurons following treatment with lactacystin. This dichotomy
could potentially be explained by the inﬁltration of activated microglia
into the degenerating SNpc in PD. Indeed we have subsequently
Fig. 3. Histone Acetylation Levels in Degenerating
Dopaminergic Neuron and Microglial Cell Cultures.
(A) Degeneration of dopaminergic neuronal cultures
induced by lactacystin was conﬁrmed using cell
viability assays (MTS, neutral red, and Bradford as-
says). (B) Activation of microglial cultures induced
by LPS was conﬁrmed using assays for TNFα and NO.
Histone acetylation (AcH3-Lys) was quantiﬁed in
degenerating N27 dopaminergic neuronal cultures
and N9 microglial cultures relative to β-Actin using
Western blot analysis. (C) Level of AcH3-Lys9 ob-
served with each treatment. (D) Representative blot
of data presented in (C). N= 3 independent re-
plicates. Statistical signiﬁcance indicated with as-
terisks: *p < .05, ***p < .001.
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demonstrated that microglial activation is associated with a marked
increase in histone acetylation, in vitro, and the extent of histone
acetylation observed in the human brain correlates closely with the
degree of the microglial marker, HLA-DPα1, and the Braak stage of the
disease. Furthermore, the neuroprotective and anti-inﬂammatory ef-
fects of SIRT 2 inhibition in vitro, and the maintained expression level of
this HDAC in the degenerating SNpc in the Parkinsonian brain, high-
light the therapeutic potential of targeting this HDAC for disease
modiﬁcation in PD.
From previous studies in cell culture systems and animal models of
neurodegenerative disease, it has been described that there is an im-
balance between the activities of HATs and HDACs in neurodegenera-
tion, in favour of histone deacetylation, thought to play a role in pa-
thogenesis and disease progression [13,43,45]. Furthermore, it has
described that αSyn accumulation itself promotes histone hypoacety-
lation, thought to be achieved through αSyn ‘masking’ acetylation sites
on histone proteins [31]. Here, in a degenerating region of the human
brain, we report the opposite: that PD development is associated with
histone hyperacetylation rather than hypoacetylation in the SNpc. It is
important to note that in previous studies, these observations were
made in homogenous populations of brain cells, for example, dopami-
nergic SH-Sy5Y cells alone in culture overexpressing αSyn in the study
by Kontopoulos et al. [31], rather than in brain tissue containing not
only dopaminergic neurons but non-neuronal brain cells too. Likewise,
our in vitro ﬁndings of dopaminergic N27 neurons alone in culture,
treated with lactacystin, are in agreement with those published pre-
viously [31], corroborating that neurodegeneration likely induces his-
tone hypoacetylation in dopaminergic neurons. In the dopaminergic
SNpc in humans however, here we observe a positive correlation of
histone acetylation with Braak staging of disease rather than a negative
one. Combined with this however we also observe a disease-dependent
increase in marker expression levels of activated microglia. In culture,
when activated, microglia displayed histone hyperacetylation. There-
fore, it is likely that in the Parkinsonian brain as the disease develops,
the reduction of dopaminergic neurons expressing histone hypoacety-
lation, combined with the inﬁltration of activated microglia expressing
histone hyperacetylation, results in a net disease-dependent increase in
the level of histone acetylation. Our correlation analyses add weight to
this proposed mechanism: histone acetylation correlating with micro-
glial marker expression directly, yet not with dopaminergic neuronal
marker expression, likely due to the extent of dopaminergic neurode-
generation and microglial inﬁltration with the development of PD.
In the current study, mRNA and protein were extracted from whole
brain tissue of the SNpc. And as has been described above, due to the
diﬀerences in cell composition (ratio of dopaminergic neurons to mi-
croglia) between control, early and late PD cases, it makes interpreta-
tion of data from such a disease-dependently varied region diﬃcult.
Cell culture studies of individual neuronal and microglial populations
were utilised in order to aid interpretation, but a number of caveats
come with the use of immortalised animal cell lines, when comparing to
data from the human brain. In contrast, isolation of select cell popu-
lations from the human SNpc, with the use of techniques such as laser
capture microdissection (LCM) would eliminate such issues, and as such
could provide direct quantiﬁcation of measures such as histone acet-
ylation and SIRT 2 expression, in degenerating neurons or activated
microglia in the SNpc. Further work should therefore seek to conﬁrm
the ﬁndings from degenerating dopaminergic neurons and activated
microglia in vitro, in select cell populations in the human SNpc using
techniques such as LCM.
In dopaminergic neurons in PD, a misbalance between the activities
of HATs/HDACs in favour of histone deacetylation is thought to result
in neurodegeneration due to dysregulation of appropriate gene ex-
pression and subsequent failure of neuronal homeostasis [13,43,45].
Consistently, here we have demonstrated that neurodegeneration of
dopaminergic neurons in vitro, is indeed accompanied by histone hy-
poacetylation. Furthermore, previous studies suggest that the observed
pathogenic histone hypoacetylation in degenerating dopaminergic
neurons can be rectiﬁed by speciﬁcally inhibiting the SIRT 2 HDAC.
Reliably, pre-treatment of N27 cells in the current study with a potent
Fig. 4. Neuroprotective Eﬀects of SIRT 2 Inhibition via AGK2 Treatment of N27Cells.
Cells were pre-treated with AGK2 (or vehicle) for 48 h prior to addition of lactacystin
(0.75 μM or vehicle) for a further 24 h. (A) MTS, (B) neutral red, and (C) Bradford assays
were then performed for quantiﬁcation of AGK2 induced neuroprotection against lacta-
cystin toxicity. Red bars indicate cells which received vehicle in place of both AGK2 and
lactacystin. Blue bars indicate cells which received vehicle in place of AGK2 treatment but
subsequently received lactacystin treatment. Green bars indicate cells treated with AGK2
and which subsequently received lactacystin treatment. N= 3 independent replicates.
Statistical signiﬁcance indicated with asterisks: *p < .05, ***p < .001.
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SIRT 2 inhibitor, AGK2, resulted in a signiﬁcant degree of neuropro-
tection at appropriate concentrations. Cytotoxicity however was ob-
served at higher concentrations of AGK2, perhaps due to excessive
histone hyperacetylation as a result of AGK2 treatment, however this
has not been directly quantiﬁed in the current study. Likewise, it has
not been ascertained in the current study as to what degree the histone
deacetylation in degenerating neurons was rectiﬁed upon treatment
with AGK2, that would result in neuroprotection in appropriate con-
centrations of AGK2. Similarly, HDACIs are thought to act neuropro-
tectively via a number of diﬀerent mechanisms, the most well under-
stood is their rectiﬁcation of neuronal homeostasis via upregulation of
neurotrophic and anti-apoptotic factors [22,47]. For example, we
showed recently that HDACI treatment in an animal model of PD results
in neuroprotection, associated with upregulation of brain derived
neurotrophic factor (BDNF), glial derived neurotrophic factor (GDNF),
and anti-apoptotic factor B-Cell Lymphoma 2 (BCL-2) [21]. The me-
chanisms mediating the neuroprotective eﬀects observed in dopami-
nergic neurons in the current study have not been investigated here,
therefore further work should aim to understand the speciﬁc neuro-
protective mechanism of SIRT 2 inhibition in this cell type, through
quantiﬁcation of such factors along with quantiﬁcation of histone
acetylation, in treated degenerating neurons. In addition to further in-
vestigation of the neuroprotective mechanism of SIRT 2 inhibition ob-
served in dopaminergic neurons here, it is important to consider whe-
ther or not the eﬀects are relevant to the speciﬁc phenotype of
dopaminergic neurodegeneration observed in PD. For example, lacta-
cystin, through its inhibition of the ubiquitin proteasome system, is
known to inhibit Nuclear Factor Kappa B (NFкB) [18], the opposite of
what is observed in dopaminergic neurons of PD patients [24]. There-
fore to determine whether SIRT 2 inhibition is likely to have a similar
neuroprotective phenotype to that observed here in lactacystin treated
dopaminergic neurons, in degenerating dopaminergic neurons in PD,
further work should aim to repeat the experiments in neuronal cultures,
with additional neurodegenerative compounds (such as 6-hydro-
xydopamine (6-OHDA), or 1-methyl-4-phenylpyridinium (MPP+ ))
modelling additional facets of the proﬁle of neurodegeneration dis-
played by dopaminergic neurons in PD.
When cultured and treated with LPS, microglia display a multi-fa-
ceted proﬁle of activation, adopting an activated amoeboid mor-
phology, upregulating pro-inﬂammatory cytokines such as TNFα, IL6
and IL1β, and activation of iNOS resulting in production of NO [33]. It
is hypothesised that upregulation of these numerous factors results from
transcriptional upregulation, via histone acetylation and chromatin
relaxation. Correspondingly, consistent with similar observations in
other microglial cell lines [39], we demonstrate here that histone
acetylation is increased when N9 microglial cells are treated with LPS,
along with increased secretion of TNFα and NO. It would therefore
appear counterintuitive that a HDAC inhibiting agent, which increases
histone acetylation and gene transcription, would result in amelioration
of microglial activation. Likewise, non-selective HDACIs Trichostatin A
and Suberoylanilide Hydroxamic acid have been previously shown to
potentiate activation and cytokine secretion in N9 microglia [51]. In
primary mouse and human microglia however, the opposite has been
described, that such non-selective HDACIs attenuate microglial activa-
tion and production of pro-inﬂammatory cytokines and NO [28,44,49].
Neither of these latter studies however conﬁrm microglial cell viability
following LPS and HDACI treatment, and given ﬁndings from Jau-
Shyong Hong’s laboratory that non-selective HDACI such as valproate
attenuate LPS induced dopaminergic neurotoxicity through HDACI
mediated microglial apoptosis [6,37], it may well be likely that the
reduced secretion of pro-inﬂammatory cytokines and NO in previous
studies is due to HDACI mediated apoptosis of microglial cells. In
contrast however, here we describe that inhibition of a select HDAC,
SIRT 2, results in attenuation of microglial activation as measured
through production of TNFα and NO. Along with this, microglial
apoptosis was conﬁrmed not to be involved: cell viability of microglial
cells after treatment with AGK2 and LPS shown not to be reduced. This
is suggestive that SIRT 2 plays a more crucial role in activation of mi-
croglia than its eﬀects as a HDAC enzyme. SIRT 2 has been previously
shown to be the most abundant HDAC endogenously expressed by
Fig. 5. Anti-Inﬂammatory Eﬀects of SIRT 2
Inhibition via AGK2 Treatment of N9Cells.
Cells were pre-treated with AGK2 (or vehicle) for
24 h prior to addition of LPS (125 ng/ml or vehicle)
for a further 24 h. (A) Griess Assay and (B) TNFα
ELISAs were then performed on the medium for
quantiﬁcation of AGK2 induced reduction of LPS
induced microglial activation. Red bars indicate cells
which received vehicle in place of both AGK2 and
LPS. Blue bars indicate cells which received vehicle
in place of AGK2 treatment but subsequently re-
ceived LPS treatment. Green bars indicate cells
treated with AGK2 and which received subsequently
received LPS treatment. (C) Cell viability assays of
each treatment of N9 cells. N=3 independent re-
plicates. Statistical signiﬁcance indicated with as-
terisks: *p < .05, **p < .01, ***p < .001.
I.F. Harrison et al. Neuroscience Letters 666 (2018) 48–57
55
microglia, which is also stringently upregulated upon activation [28],
and as such has been shown to be crucially required for LPS induced
activation of microglial cells in culture [4]. Contrastingly, it was shown
in 2013 that genetic deletion of SIRT 2 resulted in activation in the N9
microglial line, opposing the results shown here [35]. It may be the case
that in this genetic ablation study, other HDACs are upregulated in
compensation for the loss of HDAC activity: SIRT 2 being the most
abundant HDAC expressed by microglia [28]. Indeed, SIRT 2 acts as a
mitotic check point, which, during mitosis, is shuttled from its location
in the cytoplasm to the nucleus [25]. It may therefore be that SIRT 2
inhibition reduces microglial activation by direct inhibition of replica-
tion. Additionally, when microglia are activated with toll like receptor
ligands such as LPS, NFкB in the cytoplasm becomes dissociated from
inhibitors such as IкB, allowing its translocation to the nucleus and
facilitation of NFкB dependent transcription of inﬂammatory genes
[35]. Further to this, SIRT 2 interacts with the p65 subunit of NFкB,
deacetylating it at lysine 301 and thus enhancing its DNA binding ca-
pacity [30,42]. It is conceivable then that the reduction of microglial
activation, via SIRT 2 inhibition by AGK2, may be achieved through
inhibition of this mechanism rather than exacerbating the level of his-
tone acetylation observed upon activation. That being, that SIRT 2 in-
hibition would indeed result in histone hyperacetylation, leading to
greater access for transcription factors such as NFкB. However, the
reduced DNA binding capacity of NFкB induced as a result of SIRT 2
inhibition would lead to an overall reduced level of NFкB-dependent
transcription of inﬂammatory genes such as TNFα, which has been
shown here. Indeed the diﬀerence in mechanisms for mediation of SIRT
2 inhibition in neurons and microglia may account for the disparity
between eﬃcacious doses in the two cell types, observed here in vitro:
1 μM in N27 dopaminergic neurons, yet 10 μM in N9 microglia. Along
with the neuroprotective phenotype observed towards degenerating
dopaminergic neurons, our ﬁndings on the use of a SIRT 2 inhibitor in
microglia highlights the advantage of more selective HDAC inhibition,
more speciﬁcally SIRT 2 inhibition, for therapeutic potential in PD.
Given the extent of histone hyperacetylation in activated microglia,
and histone hypoacetylation in degenerating dopaminergic neurons,
the disease-dependent change observed here with PD development can
be largely accounted for. However, the contribution of astrocytes to the
level of histone acetylation has yet to be considered. Astrogliosis in the
SNpc in PD is a key feature of the disease [23], and as such histone
hyperacetylation in such reactive glia would surely contribute to the
levels of histone acetylation observed here in human SNpc tissue. Im-
portantly however, HDACI treatment of astrocytes has been shown to
increase expression and secretion levels of neurotrophic factors such as
BDNF and GDNF [5,7,54], resulting in reduced neurotoxicity, achieved
through increased promoter activity via promoter-associated histone
acetylation [54]. Additionally, HDACI treatment of astrocytes has been
noted to be associated with increased glutamate transport [53], likely
to contribute to the proposed mechanism of neuroprotection of HDACIs
in PD [22]. Furthermore, SIRT 2 inhibition speciﬁcally with AGK2 has
been observed to reduce neuroinﬂammation, via downregulation of
iNOS and Cyclooxygenase 2 (COX2) [46]. It is likely then that astro-
cytes contribute positively to the neuroprotective phenotype observed
by HDACIs in animal models of PD. Likewise, the published eﬀect of
reduced inﬂammation in astrocytes treated with SIRT 2 inhibitors
suggest that along with the eﬀects of SIRT 2 inhibition in neurons and
microglia, astrocytes would contribute to the proposed beneﬁcial ef-
fects of SIRT 2 inhibitors for therapeutic potential in PD.
5. Conclusions
We have observed here using a combination of post-mortem brain
tissue and cell culture systems, that along with dopaminergic neuro-
degeneration and microglial activation, PD development is associated
with histone hyperacetylation. Further to this, we have demonstrated
that SNpc expression levels of the HDAC SIRT 2 remain relatively
unaltered with PD development highlighting the potential of its tar-
geting in PD patients. Cell culture studies in which SIRT 2 was phar-
macologically inhibited via treatment with AGK2, demonstrate that
drug treatment results in both neuroprotection in degenerating dopa-
minergic neurons, and reduced activation in microglia. Taken together,
our ﬁndings demonstrate that SIRT 2 inhibitors warrant further in-
vestigation as potential therapeutics for the treatment of PD. More
importantly, our results highlight the need for more selective, potent
and CNS penetrant SIRT 2 inhibitors to be developed, hence enabling
the neuroprotective potential of this drug class to be fully assessed in
vivo in animal models of PD, whilst avoiding any toxic eﬀects of high
drug concentrations.
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